When is CT coronary angiography appropriate for an adult presenting with acute chest pain, a normal electrocardiogram, two negative high‑sensitivity troponin results, and intermediate risk for coronary artery disease, and what are its absolute and relative contraindications?

CT Coronary Angiography in Acute Chest Pain: When NOT to Use It

In patients with acute chest pain, normal ECG, and two negative high-sensitivity troponin results at intermediate risk, CT coronary angiography should NOT be routinely performed before discharge, as current guidelines explicitly recommend against further diagnostic testing in this low-risk population 1.

The Evidence Against Routine CCTA in This Population

The 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guidelines are unequivocal: "Do not routinely use further diagnostic testing (coronary CT angiography, stress testing, myocardial perfusion imaging) before discharge in low-risk patients in whom acute MI has been ruled out to reduce 30-day MACE" 1. This recommendation is based on the understanding that patients with:

• Nonischemic ECG
• Negative serial high-sensitivity troponin at 0 and 2 hours
• Low-risk clinical profile

...already have a sufficiently low rate of 30-day major adverse cardiovascular events (MACE) that additional testing does not improve outcomes.

The TARGET-CTCA Trial Changes Everything

The most recent and definitive evidence comes from the 2026 TARGET-CTCA trial 2, which directly tested whether routine CT coronary angiography improves outcomes in exactly this population. In 3,170 patients with suspected acute coronary syndrome where MI was ruled out (using high-sensitivity troponin >5 ng/L indicating intermediate risk), routine CT coronary angiography-guided management did not reduce the incidence of myocardial infarction or cardiac death compared to standard care (7.1% vs 7.3%; adjusted HR 0.95% CI 0.73-1.23, P=0.71) over a median 3-year follow-up 2.

This is the highest quality, most recent evidence available, and it definitively shows that routine CCTA does not improve mortality or morbidity outcomes in this population.

When CCTA May Be Considered (The Exceptions)

The 2022 ACC Expert Consensus Decision Pathway 3 provides a more nuanced framework. CCTA should be reserved for specific situations:

Appropriate Use Scenarios:

• When adequate outpatient follow-up is NOT available: If you cannot arrange follow-up within 1-2 weeks, consider further testing before discharge 1, 3
• Recurrent chest pain with previous negative CCTA >2 years ago: The SAEM GRACE-1 guidelines suggest no further testing if CCTA within 2 years showed no stenoses 1
• As part of a structured clinical decision pathway (CDP) in selected intermediate-risk patients where the result will change management 3

The Clinical Decision Pathway Approach:

The 2022 ACC guidelines 3 recommend CCTA be integrated into a CDP that combines:

• High-sensitivity troponin measurements
• Risk assessment tools (HEART score, EDACS)
• Selective use of noninvasive testing

The CDP should augment, not replace, clinical judgment 3.

Absolute and Relative Contraindications to CCTA

Absolute Contraindications:

• Severe renal dysfunction (inability to receive iodinated contrast) 4
• Severe contrast allergy (anaphylaxis to iodinated contrast)
• Pregnancy (radiation exposure)
• Inability to cooperate (cannot hold breath for 10 seconds) 4

Relative Contraindications:

• Atrial fibrillation or irregular rhythm (degrades image quality) 4
• Heart rate >65 bpm despite beta-blockade 4
• Inability to tolerate beta-blockers or nitrates 4
• Severe obesity (image quality degradation)
• Known significant CAD (CCTA not appropriate; proceed to functional testing or invasive angiography) 4
• High pretest probability of obstructive CAD (CCTA has lower specificity; proceed to functional or invasive testing) 4, 5

The Practical Algorithm

For your patient with acute chest pain, normal ECG, two negative hs-troponins, and intermediate risk:

1. Calculate risk score (HEART score, modified HEART score, or EDACS) 1, 3

2. If low risk (HEART ≤3 or EDACS <16):

   • Discharge with outpatient follow-up in 1-2 weeks 1
   • No CCTA needed 1

3. If intermediate risk AND adequate follow-up available:

   • Discharge with outpatient follow-up 1
   • Consider outpatient stress testing or CCTA if symptoms persist 1

4. If intermediate risk AND no follow-up available:

   • Consider CCTA or observation before discharge 1
   • This is the ONLY scenario where pre-discharge CCTA may be justified

5. If high risk or positive troponins:

   • Manage per NSTE-ACS guidelines 3
   • CCTA is NOT appropriate

Critical Pitfalls to Avoid

The biggest mistake is ordering CCTA reflexively in all intermediate-risk patients. The TARGET-CTCA trial 2 proves this does not improve outcomes and exposes patients to:

• Radiation (though modern protocols minimize this) 4
• Contrast nephropathy risk
• Downstream cascade of unnecessary testing from incidental findings
• Increased healthcare costs without mortality/morbidity benefit

The second major pitfall is using CCTA in high-risk patients or those with known CAD 4. These patients need functional testing or invasive angiography, not anatomic imaging.

Third, failing to ensure adequate follow-up is the only legitimate reason to perform pre-discharge testing in otherwise low-risk patients 1.

The Bottom Line

Your patient with normal ECG and two negative hs-troponins is already low-risk, regardless of their "intermediate" pretest probability. Discharge with 1-2 week follow-up is the evidence-based approach 1. CCTA should only be considered if follow-up cannot be arranged, and even then, the TARGET-CTCA trial 2 suggests it won't improve their long-term outcomes. The era of routine CCTA for chest pain rule-out is over.